WM

Perma-Fix Comments on Recently Published Department of Energy Notice

Retrieved on: 
Monday, February 6, 2023
Hanford Site, Processor register, Ecosystem, ROD, EIS, DOE, Federal Register, National Environmental Policy Act, National Environmental Engineering Research Institute, DSSI, TC, PESI, SA, U.S. Department of Energy, Office of Inspector General, WM, NEPA, Growth, Renewable energy

DOE also proposes to potentially dispose of some of these secondary wastes (after treatment) offsite at a licensed and permitted commercial disposal facility.

Key Points: 
  • DOE also proposes to potentially dispose of some of these secondary wastes (after treatment) offsite at a licensed and permitted commercial disposal facility.
  • This action would be implemented on an interim basis until such time as an enhanced onsite treatment capability is available for Direct-Feed Low-Activity Waste (DFLAW) operations (estimated to be approximately 10 years).
  • The volumes and waste types defined in this amendment reflect our core offering and represents a significant opportunity for growth in our backlog.
  • We remain committed to exceeding expectations by providing safe, commercial, waste processing to support the Hanford closure mission.”

Mustang Bio Provides CAR T Cell Therapy Portfolio Updates and 2023 Anticipated Milestones

Retrieved on: 
Monday, December 19, 2022
Dana–Farber Cancer Institute, Fred Hutchinson Cancer Research Center, Clinical trial, GBM, BPDCN, Cancer, Investigational New Drug, Infection, Glioblastoma, Translation, Food, SRT, Drug discovery, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Research, American Association for Cancer Research, MD Anderson Cancer Center, City, Birmingham, Malignancy, Leukemia, CAR, Patient, Lymphatic system, Duke University, Chronic lymphocytic leukemia, Mayo, Waldenström, Degenerative disease, Mayo Clinic, Mustang, City of Hope, Safety, Investigator, A Call for Unity, WM, University, IND, Hematological Cancer Research Investment and Education Act, Toxic epidermal necrolysis, CD20, Clinical professor, CR, Cell, Pharmaceutical industry

WORCESTER, Mass., Dec. 19, 2022 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (Nasdaq: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors and rare genetic diseases, today announced recent CAR T cell therapy portfolio updates and provided anticipated milestones for 2023.

Key Points: 
  • WORCESTER, Mass., Dec. 19, 2022 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (Nasdaq: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors and rare genetic diseases, today announced recent CAR T cell therapy portfolio updates and provided anticipated milestones for 2023.
  • Manuel Litchman, M.D., President and Chief Executive Officer of Mustang, said, “In 2022, Mustang successfully advanced our CAR T cell therapy portfolio which has laid the foundation for us to achieve multiple milestones in the coming year.
  • The combination leverages MB-108 to make cold tumors “hot,” thereby improving the efficacy of MB-101 CAR T cell therapy.
  • Additionally, Mustang plans to file an IND application for a multicenter Phase 1 clinical trial once a lead CAR construct has been identified.

Clean Energy Announces Sustainability-Linked Financing with Riverstone Credit Partners to Fund RNG Growth

Retrieved on: 
Wednesday, December 28, 2022
Public Transport, Environment, Trucking, Rail, Maritime, Transport, Oil, Gas, Alternative Energy, Energy, Logistics, Supply Chain Management, Transport, Primary energy, Credit, UPS, Natural gas, Methane, Growth, Loan Syndications and Trading Association, BP, WM, RNG, Republic Services, Los Angeles County Metropolitan Transportation Authority, Carbon, Riverstone Holdings, Riverstone, Renewable energy

Clean Energy Fuels Corp. (Nasdaq: CLNE), the largest provider of the cleanest fuel for the transportation market, today announced that it entered into a four-year $150 million sustainability-linked senior secured term loan with Riverstone Credit Partners L.P. (“Riverstone Credit Partners”), a dedicated credit investment platform focused on energy, power, decarbonization, and infrastructure managed by Riverstone Holdings LLC (“Riverstone”).

Key Points: 
  • Clean Energy Fuels Corp. (Nasdaq: CLNE), the largest provider of the cleanest fuel for the transportation market, today announced that it entered into a four-year $150 million sustainability-linked senior secured term loan with Riverstone Credit Partners L.P. (“Riverstone Credit Partners”), a dedicated credit investment platform focused on energy, power, decarbonization, and infrastructure managed by Riverstone Holdings LLC (“Riverstone”).
  • This financing provides Clean Energy with additional capital to execute its renewable natural gas (RNG) growth strategy as demand for RNG fuel rapidly rises.
  • Clean Energy’s growth strategy includes the development of negative carbon intensity RNG projects and construction of new RNG fueling stations for transportation sector customers.
  • We are thrilled to partner with them on their quest to deliver fully zero-carbon RNG by 2025,” said Daniel Flannery, Managing Director at Riverstone.

WM Sets Date for Fourth Quarter and Full-Year Earnings Release Conference Call

Retrieved on: 
Wednesday, December 21, 2022
Utilities, Construction & Property, Sustainability, Environment, Alternative Energy, Energy, Building Systems, Recycling, Interest, NYSE, WM

WM (NYSE: WM) announced that it will release fourth quarter and full-year 2022 financial results before the opening of the market on Wednesday, Feb. 1, 2023.

Key Points: 
  • WM (NYSE: WM) announced that it will release fourth quarter and full-year 2022 financial results before the opening of the market on Wednesday, Feb. 1, 2023.
  • Following the release, WM will host its investor conference call at 10 a.m.
  • Listeners can access a live audio webcast of the conference call by visiting investors.wm.com and selecting “Events & Presentations” from the website menu.
  • Participants who will be dialing in for the conference call should register to obtain their dial in and passcode details.

China Smart Parking Industry Report 2022 Featuring 19 Smart Parking Solution Providers & 4 Smart Parking Technology Companies

Retrieved on: 
Wednesday, December 21, 2022
CONNECT, ACE, General Office of the State Council, QR, Navigation, Baidu Maps, CIM, IVI, Baidu, WM, APP, Ali Baba, Tencent, Foot, Mercedes-Benz, City, Information management, Development, Research, State Council, Hospital, Renewable energy, Tunnel, Cryptocurrency, Lease, Car dealership, Huawei, Audi

DUBLIN, Dec. 21, 2022 /PRNewswire/ -- The "China Smart Parking Industry Report, 2022" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • DUBLIN, Dec. 21, 2022 /PRNewswire/ -- The "China Smart Parking Industry Report, 2022" report has been added to ResearchAndMarkets.com's offering.
  • Smart parking companies in the core circle are divided into three major camps: system integrators, intelligent hardware companies, and investors/operators.
  • Attracted by enormous potential of smart parking market, technology firms including Baidu, Alibaba, Tencent and Huawei (BATH) have also entered the market.
  • In June 2021, Baidu bought a 100% stake in Beijing Lottop Technology, aiming to shore up its weak spots in static traffic smart parking and deploy city-level smart parking.

China Smart Parking Industry Report 2022: 4,000 Players and City-Level Parking Platforms have Been Established - ResearchAndMarkets.com

Retrieved on: 
Friday, December 16, 2022
Technology, Transport, Other Technology, Construction & Property, Urban Planning, Other Transport, CONNECT, Tencent, Navigation, APP, IVI, Baidu Maps, Hospital, Ali Baba, Baidu, General Office of the State Council, Mercedes-Benz, WM, CIM, State Council, Research, ACE, QR, Foot, Information management, Development, City, Renewable energy, Tunnel, Cryptocurrency, Lease, Car dealership, Huawei, Audi

The "China Smart Parking Industry Report, 2022" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "China Smart Parking Industry Report, 2022" report has been added to ResearchAndMarkets.com's offering.
  • Smart parking research: there are 4,000 players, and city-level parking platforms have been established.
  • Smart parking companies in the core circle are divided into three major camps: system integrators, intelligent hardware companies, and investors/operators.
  • In June 2021, Baidu bought a 100% stake in Beijing Lottop Technology, aiming to shore up its weak spots in static traffic smart parking and deploy city-level smart parking.

WM Announces Plan to Increase its Dividend Rate and a New Share Repurchase Authorization

Retrieved on: 
Thursday, December 8, 2022
Utilities, Construction & Property, Sustainability, Environment, Alternative Energy, Energy, Building Systems, Recycling, Transport, Weakness, Recycling, Privacy, Collection, Natural gas, Annual report, NYSE, Investment, Overalls, Growth, Failure, Safety, Workforce, Renewable energy, Waste management, Acquisition, Risk, Holding company, Risk management, WM

WM (NYSE: WM) today announced that its Board of Directors has approved a 7.7% increase in the planned quarterly dividend rate for 2023, from $0.65 to $0.70 per share.

Key Points: 
  • WM (NYSE: WM) today announced that its Board of Directors has approved a 7.7% increase in the planned quarterly dividend rate for 2023, from $0.65 to $0.70 per share.
  • The annual dividend rate increase from $2.60 to $2.80 per share marks the twentieth consecutive year of dividend rate increases.
  • The Company also received authorization from its Board of Directors to repurchase up to $1.5 billion of the Companys common stock.
  • This new authorization replaces our prior $1.5 billion authorization that was fully utilized in 2022.

HealthWell Foundation Launches Waldenstrom Macroglobulinemia Fund

Retrieved on: 
Wednesday, December 14, 2022
Newton, Spleen, Lymphatic system, Immune system, Disease management, Weakness, IWMF, Charitable organization, Patient, Waldenström's macroglobulinemia, WM, Waldenström, Fatigue, Lymph, Liver, Disease, Quality of life, Abdomen, Caregiver, Safety, Hyperviscosity syndrome, Common, Infection, Macroglobulinemia, Blood, Insurance, Health insurance, Pharmaceutical industry, Residential care

GERMANTOWN, Md., Dec. 14, 2022 /PRNewswire/ -- The HealthWell Foundation®, an independent non-profit that provides a financial lifeline for inadequately insured Americans, is proud to announce that it has launched a new fund to provide financial assistance to patients living with Waldenstrom Macroglobulinemia. Through the new fund, HealthWell will provide up to $8,000 in copayment or insurance premium assistance to eligible patients with annual household incomes up to 500 percent of the federal poverty level to obtain prescription medications for the treatment and management of their condition.

Key Points: 
  • GERMANTOWN, Md., Dec. 14, 2022 /PRNewswire/ -- The HealthWell Foundation, an independent non-profit that provides a financial lifeline for inadequately insured Americans, is proud to announce that it has launched a new fund to provide financial assistance to patients living with Waldenstrom Macroglobulinemia.
  • Waldenstrom macroglobulinemia (WM) is a rare type of blood cancer that begins in the white blood cells and is a slow-growing cancer of the lymphatic system.
  • "We applaud the HealthWell Foundation and its donors for recognizing the undue financial burden patients face in accessing and affording their care.
  • To determine eligibility and apply for financial assistance, visit HealthWell's Waldenstrom Macroglobulinemia Fund page.

Clean Energy Renewable Natural Gas to Fuel Trucks for Pennsylvania Refuse Authority, WM and Others

Retrieved on: 
Wednesday, December 7, 2022
Oil, Gas, Trucking, Alternative Energy, Energy, Transport, Transfer, Tree, Transport, State College, Pennsylvania, Risk, RNG, Recycling, Partnership, WM, Natural gas, Energy Independence and Security Act of 2007, Development, Multimedia, Growth, News, CNG, Primary energy, Carbon, Renewable energy

(Photo: Business Wire)

Key Points: 
  • (Photo: Business Wire)
    The recycling and refuse industry has long embraced natural gas to mitigate the impact of greenhouse gas emissions, said Chad Lindholm, senior vice president, Clean Energy.
  • WM is proud to work with the Centre County Recycling and Refuse Authority and commends their transition to a cleaner, renewable fleet with renewable natural gas, said Christopher Pilzer, director of sustainable growth, WM Capitol Area.
  • WM is committed to the growth of our natural gas fleet and investing in renewable energy through RNG.
  • Our mission is to decarbonize transportation through the development and delivery of renewable natural gas (RNG), a sustainable fuel derived from organic waste.

Loxo@Lilly Presents Updated Pirtobrutinib Data from the Phase 1/2 BRUIN Clinical Trial at the 2022 American Society of Hematology Annual Meeting

Retrieved on: 
Monday, December 12, 2022
Data, Lymphoid leukemia, Lymphoma, BOR, Chemistry, Recurrence, Bruise, PK, Society, NHL, Mantle cell lymphoma, SLL, BTK, AE, Patient, Hypertension, Pharmacokinetics, Drug combination, Physician, Pharmacology, Bleeding, NYSE, Fatigue, Richter's transformation, Obesity, Multimedia, Clinical trial, University, Biotechnology, Atrial fibrillation, Eli Lilly and Company, Neutropenia, Index (publishing), Alzheimer's disease, IRC, Diarrhea, WM, PFS, Form, Non-Hodgkin lymphoma, Cancer, University of California, ASH, CLL, BCL2, LLY, ORR, MCL, Lymphocytosis, MRR, Chronic lymphocytic leukemia, Progression-free survival, Medicine, Survival, RT, Dor, MTD, Safety, Pharmaceutical industry, Lilly

INDIANAPOLIS, Dec. 12, 2022 /PRNewswire/ -- Loxo@Lilly, the oncology unit of Eli Lilly and Company (NYSE: LLY), today announced updated clinical data from the pirtobrutinib global Phase 1/2 BRUIN trial in patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), mantle cell lymphoma (MCL), Richter transformation (RT), and Waldenström macroglobulinemia (WM). Pirtobrutinib is an investigational, highly selective, reversible (non-covalent) inhibitor of Bruton's tyrosine kinase (BTK). These data are featured in oral and poster presentations at the 2022 American Society of Hematology (ASH) Annual Meeting. 

Key Points: 
  • These data are featured in oral and poster presentations at the 2022 American Society of Hematology (ASH) Annual Meeting.
  • The BRUIN Phase 1/2 clinical trial is evaluating pirtobrutinib monotherapy in patients previously treated for MCL, CLL/SLL, or other non-Hodgkin lymphomas (NHL).
  • The BRUIN trial includes one of the largest prospective cohorts of BTK inhibitor pre-treated CLL/SLL patients ever studied.
  • The trial includes a Phase 1 dose-escalation phase, a Phase 1b combination arm, and a Phase 2 dose-expansion phase.